Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11881437 | 0.86 | ALDH1A1 (0.46) | FFAR4ALDH1A1PKMCYP1A1CYP1B1 | |
| SCHEMBL3038765 | 0.86 | ALDH1A1 (0.52) | FFAR4NQO2ALDH1A1PKMPTGS2 | |
| SCHEMBL27823143 | 0.82 | PTGS2 (0.44) | FFAR4NQO2ALDH1A1PTGS2EPAS1 | |
| SCHEMBL67496 | 0.79 | ALDH1A1 (0.42) | ALDH1A1PKMPTGS2 | |
| SCHEMBL28188557 | 0.78 | RAPGEF4 (0.43) | FFAR4ALDH1A1PKMCYP1A1CYP1B1 | |
| SCHEMBL2852652 | 0.78 | FFAR4 (0.42) | FFAR4ALDH1A1PKMNAMPTCYP1A1 | |
| SCHEMBL12666576 | 0.78 | FFAR4 (0.40) | FFAR4NQO2ALDH1A1PKMNAMPT | |
| SCHEMBL19024616 | 0.77 | CYP3A4 (0.38) | FFAR4ALDH1A1PKMCYP1A1CYP1B1 | |
| SCHEMBL31314383 | 0.77 | MAPT (0.38) | FFAR4ALDH1A1PKMCYP1A1CYP1B1 | |
| SCHEMBL13584602 | 0.77 | MAPT (0.38) | FFAR4ALDH1A1PKMCYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312172-B1 | AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10479780-B2 | Aminopyrazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-11-19 | — | — | US | disclosed |
| WO-2016204261-A1 | AMINOPYRAZOLE DERIVATIVES | 中外製薬株式会社 | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479780-B2 | Aminopyrazole derivatives | SRC, GRK2, GRK3 | FFAR4 3546/4885NQO2 1215/4885ALDH1A1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.